LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Home・Aktien・Design Therapeutics Inc

Design Therapeutics Inc

Geschlossen

10.02 0.8

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

9.89

Max

10.15

Schlüsselkennzahlen
By Trading Economics
Einkommen	2.1M -17M
Angestellte	55
EBITDA	4.7M -17M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+44.79% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	9. März 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	218M 591M
Vorheriger Eröffnungskurs	9.22
Vorheriger Schlusskurs	10.02

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

3.26 / 3.63 Unterstützung & Widerstand

Design Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

13. Feb. 2026, 16:32 UTC

Ergebnisse

Enbridge, TC Energy Investing in Opportunities to Tap Rising Energy Demand, Boom in Data Centers -- Update

13. Feb. 2026, 21:57 UTC

Ergebnisse

Stocks Rise on Softer Inflation Data, but AI Jitters Trigger Worst Week Since November -- WSJ

13. Feb. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

13. Feb. 2026, 21:20 UTC

Ergebnisse

Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More Stock Market Movers -- Barrons.com

13. Feb. 2026, 21:05 UTC

Akquisitionen, Fusionen, Übernahmen

Constellation Software: Lumine Group Completes Acquisition of Synchronoss Technologies >CSU.T SNCR

13. Feb. 2026, 20:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

13. Feb. 2026, 20:45 UTC

Market Talk

Dollar Pares Down Early Losses -- Market Talk

13. Feb. 2026, 20:39 UTC

Market Talk

Potential for Mild Winter Ahead Sinks Natural Gas for Week -- Market Talk

13. Feb. 2026, 20:28 UTC

Market Talk

Oil Settles Week Lower -- Market Talk

13. Feb. 2026, 19:51 UTC

Ergebnisse

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

13. Feb. 2026, 19:32 UTC

Market Talk

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

13. Feb. 2026, 19:32 UTC

Market Talk

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

13. Feb. 2026, 19:29 UTC

Ergebnisse

Big Tech's Spending Spree Could Limit Buybacks and Dividends -- Barrons.com

13. Feb. 2026, 18:18 UTC

Akquisitionen, Fusionen, Übernahmen

Exxon, Walmart and 9 Other Stocks That Are Soaring Because Cash Is King Again -- Barrons.com

13. Feb. 2026, 17:52 UTC

Ergebnisse

Pinterest's Earnings Give More Proof of Meta Platform's Dominance -- Barrons.com

13. Feb. 2026, 17:16 UTC

Ergebnisse

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

13. Feb. 2026, 17:10 UTC

Akquisitionen, Fusionen, Übernahmen

Vibe-Coding in Gas Town? A Guide to the Software Selloff With 4 Sexy Stock Picks. -- Barrons.com

13. Feb. 2026, 16:59 UTC

Ergebnisse

AppLovin Stock Stabilizes After Selloff. Its Biggest Critic Waves the White Flag. -- Barrons.com

13. Feb. 2026, 16:39 UTC

Akquisitionen, Fusionen, Übernahmen

Berkshire Might Have Sold More Apple, Bank of America Stock in Fourth Quarter -- Barrons.com

13. Feb. 2026, 16:11 UTC

Ergebnisse

Nvidia Stock Wobbles. The Focus Is Turning to Earnings. -- Barrons.com

13. Feb. 2026, 16:07 UTC

Market Talk

Hungarian Forint Could Rise Further -- Market Talk

13. Feb. 2026, 15:54 UTC

Ergebnisse

Detroit Automakers Take $50 Billion Hit as EV Bubble Bursts -- WSJ

13. Feb. 2026, 15:26 UTC

Market Talk

Indian Imports of Saudi Crude Hit Highest Since 2022 -- Market Talk

13. Feb. 2026, 15:01 UTC

Ergebnisse

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Steel Dynamics, Coinbase, DraftKings, Tri Pointe Homes, and More -- Barrons.com

13. Feb. 2026, 15:00 UTC

Ergebnisse

Expedia Falls, but Airbnb Rises. Why Online Travel Stocks Face a Tough Year. -- Barrons.com

13. Feb. 2026, 14:50 UTC

Market Talk

Oil Moves Lower As Market Weighs Geopolitical Risk -- Market Talk

13. Feb. 2026, 14:44 UTC

Ergebnisse

Arista Networks Stock Climbs. Why It Is Outshining Cisco. -- Barrons.com

13. Feb. 2026, 14:22 UTC

Market Talk

Ergebnisse

Global Energy Roundup: Market Talk

13. Feb. 2026, 14:21 UTC

Market Talk

Ergebnisse

TC Energy's Broadly Anticipated Results Expected To Have Neutral Response -- Market Talk

13. Feb. 2026, 14:13 UTC

Market Talk

U.S. Natural Gas Futures Move Lower -- Market Talk

Peer-Vergleich

Kursveränderung

Design Therapeutics Inc Prognose

Kursziel

By TipRanks

44.79% Vorteil

12-Monats-Prognose

Durchschnitt 15 USD 44.79%

Hoch 18 USD

Tief 13 USD

Basierend auf 4 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Design Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

4 ratings

Buy

Halten

Sell

Basierend auf 4 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Design Therapeutics Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

3.26 / 3.63Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

All events are bearish.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Design Therapeutics Inc

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.